Specialty Drug “Value-Based” Formulary Tiering Needs Transparency – AMA
The American Medical Association is concerned that "value-based" formulary tiering structures will lack sufficient transparency regarding patients' out-of-pocket costs for specialty pharmaceuticals
You may also be interested in...
Managed care plans increasingly are moving toward selecting preferred biologic agents within a therapeutic class, WellPoint VP & Chief Pharmacy Officer Robert Seidman said
The Pharmaceutical Research & Manufacturers of America's principles for the use of evidence-based medicine emphasize that such data be used to "empower" patients and physicians
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011